| Trial ID: | L6101 |
| Source ID: | NCT05184322
|
| Associated Drug: |
T2026
|
| Title: |
XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Obesity|Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: T2026|DRUG: Placebo|DRUG: Oral ecnoglutide tablet|DRUG: Oral ecnoglutide tablet|DRUG: Oral ecnoglutide tablet|DRUG: Oral ecnoglutide tablet|DRUG: Oral ecnoglutide tablet|DRUG: Oral ecnoglutide tablet|DRUG: T2026|DRUG: Placebo|DRUG: T2026|DRUG: Placebo
|
| Outcome Measures: |
Primary: Number and percentage of treatment emergent adverse events (TEAEs) and serious adverse events (SAE), Count of adverse events, Up to 98 days |
|
| Sponsor/Collaborators: |
Sponsor: Sciwind Biosciences APAC CO Pty. Ltd. | Collaborators: Hangzhou Sciwind Biosciences Co., Ltd.|Sciwind Biosciences USA Co., Ltd.
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
90
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2022-04-12
|
| Completion Date: |
2024-08-01
|
| Results First Posted: |
|
| Last Update Posted: |
2024-06-28
|
| Locations: |
Q-Pharm Pty Ltd (AKA Nucleus Network Brisbane), Herston, Queensland, 4006, Australia
|
| URL: |
https://clinicaltrials.gov/show/NCT05184322
|
